PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Official Title

A Multicentre, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer


The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Trial Description

Primary Outcome:

  • Phase 2a (PLX2853 monotherapy): overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)
  • Phase 1b (PLX2853 + carboplatin combination): establish the MTD/RP2D for the combination of PLX2853 and carboplatin
  • Phase 2a (PLX2853 + carboplatin combination): ORR as measured by RECIST v1.1
Secondary Outcome:
  • Incidence of TEAEs that are related to treatment (both arms)
  • Incidence of TEAEs that result in dose interruption, reduction or discontinuation (both arms)
  • Incidence of treatment-emergent ECG abnormalities (both arms)
  • Incidence of treatment-emergent laboratory abnormalities (both arms)
  • Duration Of Response (DOR) (both arms)
  • Disease control rate (DCR) (both arms)
  • Progression-free survival (PFS) (both arms)
  • Overall survival (OS) (both arms)
  • PLX2853 PK parameter AUC0-last (both arms)
  • PLX2853 PK parameter AUC0-24 (both arms)
  • PLX2853 PK parameter AUC0-∞ (both arms)
  • PLX2853 PK parameter Cmax (both arms)
  • PLX2853 PK parameter Tmax (both arms)
  • PLX2853 PK parameter T1/2 (both arms)
  • PLX2853 PK parameter accumulation ratio at steady state (both arms)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society